Benzinga | Jan 31, 2022 08:42AM EST

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $754

Truist Securities analyst Robyn Karnauskas maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $756 to $754.